MJ33

MJ-33 is a competitive phospholipase A₂ (PLA₂) inhibitor. MJ-33 inhibits the activation of NOX2 by blocking the PLA₂ activity of Prdx6, thereby reducing the production of ROS. MJ-33 effectively inhibits the activity of acidic PLA₂ (pH 4.0), reduces the degradation of pulmonary surfactant phosphatidylcholine (PC), but has no effect on alkaline PLA₂ (pH 8.5) . MJ-33 significantly alleviates lung oxidative damage induced by ischemia-reperfusion (I/R) . MJ-33 significantly inhibits the invasive, migratory and adhesive abilities of prostate cancer cells by suppressing the MAPK, AKT, NF-κB and AP-1 signaling pathways. MJ-33 can be used to study ROS-related diseases and prostate cancer[1][2][3].

Product Specifications

CAS Number

[137300-78-8]

UNSPSC

12352211

Target

Akt; AP-1; NADPH Oxidase; NF-κB; p38 MAPK; Phospholipase; Reactive Oxygen Species (ROS)

Related Pathways

Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology; Cardiovascular Disease

Smiles

O=P(OC)(O)OC(COCCCCCCCCCCCCCCCC)COCC(F)(F)F

Molecular Formula

C22H44F3O6P

Molecular Weight

492.55

References & Citations

[1]Hour MJ, et al. Antitumor effects of the novel quinazolinone MJ-33: Inhibition of metastasis through the MAPK, AKT, NF-κB and AP-1 signaling pathways in DU145 human prostate cancer cells. International journal of oncology. 2012 Oct 1;41 (4) :1513-9.|[2]Lee I, et al. A novel nontoxic inhibitor of the activation of NADPH oxidase reduces reactive oxygen species production in mouse lung. The Journal of pharmacology and experimental therapeutics. 2013 May 1;345 (2) :284-96.|[3]Fisher AB, et al. A competitive inhibitor of phospholipase A2 decreases surfactant phosphatidylcholine degradation by the rat lung. Biochemical Journal. 1992 Dec 1;288 (2) :407-11.